Physician profile
Philip Stromquist
NPI 1447358783
$1,790.41
in general payments reported to CMS, 2019-2025
10 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $213 · 2021: $257 · 2022: $368 · 2023: $129 · 2024: $353 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582 · Travel and Lodging: $17.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.58 |
| Travel and Lodging | $17.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $953.59 | 2019-2022 | |
| Recor Medical INC | $310.45 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Abbott Laboratories | $176.15 | 2022-2024 | Optis, Mitraclip, Coroflow |
| Shockwave Medical, INC | $142.31 | 2022 | |
| Terumo Medical Corporation | $50.26 | 2023-2024 | Metacross Otw, Angio-Seal |
| Medtronic, INC. | $44.66 | 2023-2024 | Resolute Onyx, Symplicity G3 |
| Abiomed | $42.34 | 2021 | |
| Teleflex LLC | $29.81 | 2022 | |
| Cordis US Corp. | $23.98 | 2024 | Mynx Control |
| Cardiva Medical, INC. | $16.86 | 2024 | Cardiva Vascade 6/7f Vcs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Stromquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.